Pfizer Inc. (NYSE:PFE - Get Free Report) shares shot up 1.6% during mid-day trading on Friday . The stock traded as high as $26.36 and last traded at $26.18. 15,926,336 shares were traded during trading, a decline of 59% from the average session volume of 38,610,910 shares. The stock had previously closed at $25.77.
Several research firms have weighed in on PFE. Guggenheim dropped their price objective on Pfizer from $35.00 to $33.00 and set a "buy" rating for the company in a report on Wednesday, December 11th. Bank of America reissued a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Wolfe Research started coverage on shares of Pfizer in a report on Friday, November 15th. They issued an "underperform" rating and a $25.00 price objective on the stock. Citigroup started coverage on shares of Pfizer in a report on Friday, October 25th. They set a "neutral" rating and a $30.00 price target on the stock. Finally, StockNews.com cut shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, November 20th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, Pfizer currently has a consensus rating of "Moderate Buy" and a consensus target price of $32.14.
Get Our Latest Stock Analysis on PFE
The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business has a 50-day moving average price of $26.88 and a two-hundred day moving average price of $28.20. The firm has a market cap of $149.84 billion, a PE ratio of 35.73, a PEG ratio of 0.63 and a beta of 0.65.
Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same period last year, the company earned ($0.17) EPS. The firm's quarterly revenue was up 31.2% on a year-over-year basis. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a $0.43 dividend. The ex-dividend date is Friday, January 24th. This is an increase from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.51%. Pfizer's dividend payout ratio (DPR) is currently 232.43%.
In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.06% of the company's stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PFE. State Street Corp grew its holdings in Pfizer by 1.2% in the 3rd quarter. State Street Corp now owns 290,460,600 shares of the biopharmaceutical company's stock valued at $8,405,930,000 after buying an additional 3,405,539 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Pfizer by 11.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock worth $3,766,366,000 after acquiring an additional 12,864,343 shares during the last quarter. Geode Capital Management LLC raised its position in Pfizer by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company's stock worth $3,392,342,000 after purchasing an additional 1,855,419 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Pfizer by 3.2% during the second quarter. Massachusetts Financial Services Co. MA now owns 71,794,056 shares of the biopharmaceutical company's stock valued at $2,008,798,000 after acquiring an additional 2,241,609 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Pfizer by 22.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company's stock valued at $1,101,713,000 after purchasing an additional 6,977,587 shares during the last quarter. Institutional investors own 68.36% of the company's stock.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.